Recent Updates
Recently added Catalysts
ADMA Negative Sentiment Score: 15/100

ADMA STOCK ALERT: Why is ADMA Biologics being Sued for Securities Fraud? Investors that Lost Money are Notified to Contact BFA Law after Stock Drops 20% (Nasdaq:ADMA)

Key Takeaway: ADMA Biologics, Inc. is under investigation for potential violations of federal securities laws following the unexpected resignation of its independent auditor. This event has significantly impacted the company's stock price, leading to a more than 20% decline since October 9, 2024. Investors who lost money as a result of this decline are being informed of their legal options. Leading law firm Bleichmar Fonti & Auld LLP is spearheading the investigation and encourages affected shareholders to seek representation.

Market Sentiment Analysis

CONCERNS & RISKS

  • ADMA Biologics is facing a securities fraud investigation, indicating potential misconduct.
  • The resignation of its independent auditor has contributed to a 20% stock drop.
  • Investors are encouraged to pursue legal action, highlighting financial losses.

Full Press Release Details

NEW YORK, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ: ADMA) for potential violations of the federal securities laws.
If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/adma-biologics-inc.
Why Did ADMA Biologics’s Stock Drop?
ADMA Biologics is an end-to-end commercial biopharmaceutical company that manufactures, markets and develops specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases.
On October 9, 2024, ADMA Biologics disclosed the surprise resignation of its independent outside auditor CohnReznick LLP.
The news has caused a precipitous decline in the price of ADMA Biologics stock. During trading on October 10, 2024, the price of ADMA Biologics stock declined more than 20%.
If you invested in ADMA Biologics you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.
Submit your information by visiting:
Why Bleichmar Fonti & Auld LLP?
Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs’ Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors (pending court approval), as well as $420 million from Teva Pharmaceutical Ind. Ltd.
For more information about BFA and its attorneys, please visit https://www.bfalaw.com.
Attorney advertising. Past results do not guarantee future outcomes.

Tags

Frequently Asked Questions

What triggered the stock drop of ADMA Biologics?

ADMA Biologics's stock fell sharply after the unexpected resignation of its auditor, CohnReznick LLP.

How much did ADMA Biologics's stock decline?

The stock price decreased by over 20% during trading on October 10, 2024.

Who is investigating ADMA Biologics?

The securities law firm Bleichmar Fonti & Auld LLP is conducting an investigation.

What services does Bleichmar Fonti & Auld LLP offer?

The firm represents plaintiffs in securities class actions and shareholder litigation.

How can investors get more information?

Investors can visit Bleichmar Fonti & Auld's website for additional details.

Last updated: Oct 23, 2024